Bio-Techne (TECH) Shares Bought by Bamco Inc. NY

Bamco Inc. NY boosted its stake in shares of Bio-Techne (NASDAQ:TECH) by 0.2% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 1,520,323 shares of the biotechnology company’s stock after acquiring an additional 3,348 shares during the period. Bio-Techne comprises about 1.1% of Bamco Inc. NY’s holdings, making the stock its 23rd biggest holding. Bamco Inc. NY’s holdings in Bio-Techne were worth $229,630,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the business. Amalgamated Bank raised its position in Bio-Techne by 5.4% during the fourth quarter. Amalgamated Bank now owns 7,772 shares of the biotechnology company’s stock worth $1,007,000 after acquiring an additional 399 shares during the period. Meadow Creek Investment Management LLC raised its position in Bio-Techne by 14.3% during the fourth quarter. Meadow Creek Investment Management LLC now owns 3,520 shares of the biotechnology company’s stock worth $456,000 after acquiring an additional 440 shares during the period. Jane Street Group LLC raised its position in Bio-Techne by 17.5% during the fourth quarter. Jane Street Group LLC now owns 3,016 shares of the biotechnology company’s stock worth $391,000 after acquiring an additional 449 shares during the period. Advisor Group Inc. raised its position in Bio-Techne by 64.5% during the fourth quarter. Advisor Group Inc. now owns 1,288 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 505 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Bio-Techne by 28.7% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,662 shares of the biotechnology company’s stock worth $402,000 after acquiring an additional 593 shares during the period. Institutional investors own 98.22% of the company’s stock.

Shares of Bio-Techne opened at $151.62 on Friday, according to MarketBeat.com. The stock has a market capitalization of $5.61 billion, a PE ratio of 44.33, a price-to-earnings-growth ratio of 2.46 and a beta of 0.72. The company has a quick ratio of 4.30, a current ratio of 5.55 and a debt-to-equity ratio of 0.37. Bio-Techne has a 52 week low of $149.61 and a 52 week high of $151.80.

Bio-Techne (NASDAQ:TECH) last issued its earnings results on Wednesday, May 2nd. The biotechnology company reported $1.21 EPS for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.07. The business had revenue of $164.00 million during the quarter, compared to analysts’ expectations of $163.43 million. Bio-Techne had a net margin of 18.29% and a return on equity of 14.75%. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.97 earnings per share. equities research analysts predict that Bio-Techne will post 4.05 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 25th. Investors of record on Monday, May 14th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend is Friday, May 11th. Bio-Techne’s dividend payout ratio is currently 37.43%.

A number of equities research analysts have recently commented on TECH shares. Zacks Investment Research cut shares of Bio-Techne from a “buy” rating to a “hold” rating in a research report on Thursday, May 3rd. Deutsche Bank reduced their target price on shares of Bio-Techne from $167.00 to $165.00 and set a “buy” rating for the company in a research report on Thursday, May 3rd. Leerink Swann set a $160.00 target price on shares of Bio-Techne and gave the company a “buy” rating in a research report on Thursday, May 3rd. ValuEngine upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, BidaskClub upgraded shares of Bio-Techne from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 16th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $150.83.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne (NASDAQ:TECH).

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply